Skip to Content
Merck
  • An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.

An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.

The Journal of dermatological treatment (2010-06-12)
Rosita Saraceno, Andrea Chiricozzi, Steven Paul Nisticò, Sergio Tiberti, Sergio Chimenti
ABSTRACT

Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus. To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis. Twelve patients were enrolled in this pilot comparison of betamethasone valerate 0.1% tape versus a moisturizing itch-relief cream containing feverfew. The study period was 4 weeks. Clinical evaluation was performed weekly. Eleven subjects completed the 4 weeks of therapy. The mean visual analogue scale (VAS) for pruritus at baseline was 8.75 for both sides of the body. The side treated with betamethasone valerate 0.1% tape showed a higher clinical response (VAS score at week 4: 3.9; p < 0.005) compared with the side treated with moisturizing itch-relief cream (VAS score at week 4: 5.6; p < 0.005). Both treatments were effective. However, the occlusive dressing enhanced the efficacy of the treatment, preventing scratching.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Betamethasone 17-valerate
Supelco
Betamethasone 17-valerate, VETRANAL®, analytical standard
Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard
Betamethasone valerate for system suitability, European Pharmacopoeia (EP) Reference Standard